key: cord-0841954-wk4ecjmj
authors: Yelin, Dana; Moschopoulos, Charalampos D.; Margalit, Ili; Gkrania-Klotsas, Effrossyni; Landi, Francesco; Stahl, Jean-Paul; Yahav, Dafna
title: ESCMID rapid guidelines for assessment and management of long COVID
date: 2022-02-17
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.018
sha: 4126583bb418a394cb657415f24f23363d256e6e
doc_id: 841954
cord_uid: wk4ecjmj

SCOPE: The aim of these guidelines is to provide evidence-based recommendations for assessment and management of individuals with persistent symptoms after acute COVID-19 infection, and provide a definition for this entity, termed “long COVID”. METHODS: We performed a search of the literature on studies addressing epidemiology, symptoms, assessment, and treatment of long COVID. The recommendations were grouped by these headings and by organ systems for assessment and treatment. An expert opinion definition of long COVID is provided. Symptoms were reviewed by a search of the available literature. For assessment recommendations, we aimed to perform a diagnostic meta-analysis, but no studies provided relevant results. For treatment recommendations we performed a systematic review of the literature in accordance with the PRISMA statement. We aimed to evaluate patient-related outcomes, including quality of life, return to baseline physical activity, and return to work. Quality assessment of studies included in the systematic review is provided according to study design. RECOMMENDATIONS: Evidence was insufficient to provide any recommendation other than conditional guidance. The panel recommends considering routine blood tests, chest imaging and pulmonary functions tests for patients with persistent respiratory symptoms at 3 months. Other tests should be performed mainly to exclude other conditions according to symptoms. For management, no evidence-based recommendations could be provided. Physical and respiratory rehabilitation should be considered. On the basis of limited evidence, the panel suggests designing high quality prospective clinical studies/trials, including a control group, to further evaluate assessment and management of individuals with persistent symptoms of COVID-19.

The WHO defines "post COVID-19 condition" as persistent symptoms and/or signs, developing during or after an acute COVID-19 illness, lasting for at least 2 months and persisting beyond 12 weeks from the acute disease and cannot be explained by an alternative diagnosis [17] . The CDC provides a similar definition, with a different timeframe of beyond 4 weeks post the acute disease. [18] The Royal Society defines the same condition, however no time frame is provided. [17] A similar term called post-acute sequelae of SARS-CoV-2 infection (PASC) has been termed by the National institute of Health (NIH). [19] A repository of published/available definitions of post COVID-19 condition is maintained by the WHO. [17] While no consensus regarding a single term for long COVID/post COVID-19 condition has been obtained by a WHO Delphi process, [17] in the current guidelines we have used the term "long COVID". Table 1 provides the definitions used for long COVID for the purposes of this document.

Long COVID is defined here as one or more symptoms and/or signs (as described below) persisting or relapsing/remitting for more than 12 weeks since an acute COVID-19 diagnosis, without an alternative explanation. This condition can affect all individuals who encountered COVID-19, regardless of the severity of the acute disease. The syndrome can be definite, probable or possible according to the level of certainty of the original acute COVID-19

infection (see Table 1 ). Post-acute COVID: We define post-acute COVID as one or more symptoms and/or signs (as described below) persisting or relapsing/remitting from 4 to 12 weeks since confirmed acute COVID-19 diagnosis, without an alternative diagnosis. This definition also includes several specific entities (thyroiditis, myocarditis, venous thromboembolism) that may appear during this period.

J o u r n a l P r e -p r o o f Across systematic reviews/meta-analyses, the most commonly observed symptoms among long COVID patients are fatigue (31-58%), dyspnea (24-40%) , musculoskeletal pain (9-19%), anosmia/dysgeusia (10-22%), cognitive impairment ('brain fog') (12-35%), sleep disturbances (11-44%), cough (7-29%), and chest pain (6-17%) . [20] [21] [22] [23] [24] [25] [26] Table 2 provides a summary of reported symptoms and their respective prevalence ranges. Tables 3 & 4 provide symptom prevalence according to time intervals from the acute illness (1-3m, 3-6m, >6m) and hospitalization status, respectivelyPersisting symptoms seem to considerably affect the patients' quality of life and return to daily activities and work. A systematic review of 39 studies found that decreased quality of life was reported among 57% of patients with symptoms persisting beyond 12 weeks. [27] Follow-up studies report persistence of long COVID symptoms up to 12 months after the acute disease. [28, 29] The pathophysiologic mechanisms that underlie this disorder remain largely unknown, but available data implicate the multisystemic nature of COVID-19, immune dysregulation, autoimmunity and the neurotropism of SARS-CoV-2. [4, 22, 30] Post-intensive care syndrome may provide an explanation for prolonged symptoms following critical COVID-19. This syndrome encompasses new or worsening abnormalities in physical, cognitive and psychiatric domains after critical illness. [31] For patients who have long COVID symptoms after critical care, it is difficult to distinguish whether persisting symptoms are caused by SARS-CoV-2 infection or post-intensive care syndrome.

Data on potential factors associated with increased risk of developing specific long COVID symptoms are accumulating in the literature though the evidence is inconsistent. The two consistent risk factors for any long COVID symptom are acute COVID-19 severity and gender. [32] [33] [34] (See Supplemental Table 1 ) Women have been shown to have an estimated two-fold risk of having long COVID symptoms (odds ratios between 1. 3 and 5) . Similarly, severe acute disease has been associated with increased risk for long COVID symptoms, with J o u r n a l P r e -p r o o f strongest association with fatigue. Other risk factors such as age, obesity and presence of comorbidities have shown mixed results. (Supplemental Table 1 ).

We aimed to answer the following PICO questions: 1) Who should be assessed?; 2) What assessment needed for individuals with long COVID ? (sub-divided according to systems and further subdivided by specific tests); 3) How to manage individuals with long COVID? (also sub-divided according to systems). Each section reports the main summary of evidence for each topic. Tables 5-6 provide details of the studies included.

In symptomatic patients, other serious / life-threatening conditions should be ruled out prior to considering long COVID. These include prior overlooked conditions (e.g., malignancy), or complications of acute COVID-19 (e.g., thromboembolic events, myopericarditis, encephalitis). The investigation for other conditions should be guided by symptoms, signs, and other tests, performed according to the physician's discretion. Long COVID is a diagnosis of exclusion.

Recommendation: As a first step, it is suggested to collect specific clinical history to rule out previous underlying conditions, as well as iatrogenic causes or complications related to the acute episode. Hence, any patient with persisting or new symptoms that last over 12 weeks after acute COVID-19, should be referred to medical care. For patients 4-12 weeks following acute infection, assessment should be considered on a case-by-case basis, according to the severity and course of symptoms.

J o u r n a l P r e -p r o o f

Few studies have assessed the use of routine blood tests in patients with long COVID. Huang et al., at a follow up of 12 months after COVID-19 hospitalized patients, demonstrated low rates of laboratory abnormalities, and no significant difference in rates of lymphocyte count < 0·8 × 10⁹ per L or serum creatinine abnormality between recovering participants and controls. Nevertheless, as suggested above, blood tests according to symptoms, should be collected as part of an investigation to rule out other conditions. Some blood tests may be considered in order to identify possible complications following acute infection. These however, should be interpreted with caution, due to possible persistent abnormalities following COVID-19. In one study evaluating 734 severe patients 28 days post recovery, an increase in insulin dependency from 18% to 63%, and 1.4% of new onset diabetes were identified. [35] Two additional studies found an increase in new onset diabetes in the months following recovery from COVID-19. [36, 37] This might be a result of surveillance bias in previously unknown diabetics or a real shift from pre-diabetes to diabetes, caused by the acute disease or by its' treatment, although there is no evidence for the latter. Elevated D-dimer can be observed at a median of over 2 months following resolution of acute COVID-19, despite normalization of inflammatory markers and other coagulation parameters. [38] Similarly, detectable levels of high-sensitivity troponin T (hsTnT, greater than 3 pg/mL) were reported in 71/100 patients evaluated at a median of 71 days (IQR 64-92) after diagnosis of COVID-19; with 5/100 patients having significantly elevated hsTnT (greater than 13.9 pg/mL). [39] Increased NT-pro-BNP levels at median follow up of 71 (14-124 days) were reported from a systematic review in 10% of individuals tested (57/571). [40] A systematic review accumulated data on 27 patients presenting with subacute thyroiditis following COVID-19. Patients presented with typical features, including elevated fT4 and fT3, low TSH and raised inflammatory markers (CRP and ESR). [41] J o u r n a l P r e -p r o o f Recommendation: As recommended by other guidelines, [5] [6] [7] the following may be considered for symptomatic patients according to symptoms: C-reactive protein, blood count, kidney function, and liver function tests. Consider troponin, CPK-MB, and B-type natriuretic peptide (BNP) for cardiac symptoms, and complete thyroid function tests to rule out thyroiditis, if clinically suspected. For patients with decreased oxygen saturation, blood gases are recommended by some guidelines, though the benefit of this test is limited. D-dimer should not be used in patients without respiratory symptoms. Patients at increased risk for diabetes or impaired fasting glucose should be monitored for fasting glucose and glycated hemoglobin levels.

After ruling out other conditions, the followings are suggested to evaluate individuals with suspected long COVID. First, the evaluation should include an interview with the patient to identify symptoms' severity and their impact on quality of life. Physicians should consider whether further assessment is needed for symptoms that are self-limited and without an effective and safe therapy (See below options for therapy that can be considered in the context of clinical trials).

In previous guidelines/recommendations, [5] [6] [7] a diagnostic pathway is suggested for patients with dyspnea persisting more than 4-12 weeks after acute COVID-19. Several studies used the Modified medical research council (mMRC) dyspnea scale to assess severity of dyspnea, however without providing a cut-off necessitating further investigation. [42, 43] J o u r n a l P r e -p r o o f

Various rates of abnormal PFT have been reported in recovering patients, depending on definitions of abnormality, duration of follow-up, baseline (pre-COVID) pulmonary function, and mainly acute COVID-19 severity and need for ventilatory support. [44] . The most frequently impaired pulmonary function test is diffusion capacity (DLCO), and the most frequent pattern observed is restrictive. DLCO impairment (below 80% of predicted) has been found in varying proportions of patients, in correlation to disease severity. Patients following critical disease and ICU admission had up to 80% abnormal DLCO at discharge and 50-70% impairment at 3 months follow-up. Patients following severe disease had 30-68% impairment at 3 months. [44, 45] At 3 months, higher CT severity score and ARDS at acute disease were associated with impaired DLCO in one study including hospitalized patients. [44] Surprisingly, even among patients following mild-moderate disease, abnormal DLCO was demonstrated in ~10%. [45] Future progression to pulmonary fibrosis has been raised as a concern. [46] When tested at 6 months, patients exhibited somewhat lower rates of abnormalities then at 3 months, though still high (DLCO reduced in 29% for severe 58% for critical). [47] This correlates with the finding that on serial testing of patients with restrictive pattern, tested individuals demonstrated overall improvement at 6 months compared to 10 weeks but not complete resolution. [48, 49] At a longer follow up of one year, Huang et al. reported DLCO<80% in 23%-54% of 243 patients with severe-critical acute COVID-19. Total lung capacity less than 80% of predicted decreased among critically ill patients from 39% at 6 months, but was still considerable, 29%, at 12 months. [29] There is a paucity of data for mild-moderate patients. Several of the studies included some patients following mild-moderate disease, mostly as a control group for the severe patients.

J o u r n a l P r e -p r o o f [47, 50, 51] These studies reported normal median PFTs and DLCO but a considerable percentage (10-22%) of patients still had abnormal results.

Recommendation: Evidence is insufficient to provide a recommendation for or against PFT.

Considering that the test is simple and non-invasive, and that future studies may suggest beneficial treatment for patients with abnormal PFT, the panel recommends considering routine PFT including diffusion capacity in all severe and critical COVID-19 patients at 3 months from diagnosis, regardless of symptoms; as well as considering completing PFT with diffusion for patients complaining of persistent dyspnea at 3 months following the acute disease and for patients with known prior lung disease.

 Chest X-ray Two observational studies investigating follow-up chest X-ray in COVID-19 patients at 6-8 weeks concluded that it is a poor marker for recovery, demonstrating correlation to severity of initial disease but not to ongoing symptoms. [52, 53] Three additional small observational studies reported conflicting findingsone found reticular opacities/peripheral atelectasis in 88% and ground-glass opacities in 61% of X-rays performed at 8-12 weeks; the other two studies found only 12% and 7% abnormalities. [51, 54, 55] (Table 5 ) Long follow up data are lacking. Among survivors of SARS and MERS severe illness, chest X-ray was found to have residual abnormalities in about a third of patients at 3 and even 6 months. [56, 57] No studies have correlated abnormal chest X-ray with clinical outcomes.

Recommendation: Evidence is insufficient to provide a recommendation for or against chest X-ray. Chest X-ray may be considered in long COVID patients with persistent respiratory J o u r n a l P r e -p r o o f symptoms at 3 months to rule out other diagnoses and for possible early diagnosis of pulmonary fibrosis.

 Chest CT/MRI Chest CT in patients post severe and critical disease frequently shows abnormalities, mainly ground glass opacities (GGO), consolidations and fibrotic changes. These changes are reported in ~60-75% at 3 months. [42, 54, [58] [59] [60] A systematic review summarizing chest CT findings at 3-6 month after COVID-19 with any severity, rates of polled CT abnormalities were 59% (IQR 44-73%), with GGO being the most prevalent pattern (39%, IQR 26-52%), flowed by fibrosis and reticulation (each ~30%). [26] According to two studies including ~500 patients, approximately 60% still had parenchymal findings at 6 months. [61, 62] In one of these studies, fibrotic-like changes were reported in 35% (40/114) of patients. [62] These findings correlated with older age and severity of the acute disease, and were reported regardless of ongoing symptoms. It is still unknown whether these findings predict future lung impairment. Later chest CT follow up results were reported by Huang et al. for hospitalized patients at 12-month post acute COVID. This study reported abnormal CT finding at 1year for 55% (65/118) of patients, with GGO in 46%, mainly derived from critically ill patients, who had abnormalities in 87% of exams. [29] Chest MRI was performed on 53 recovering patients at 2-3 months, showing parenchymal abnormalities in 60% (32/53), without clear clinical correlation. [63] Limited data are available to report the long-term chest CT findings in mild-moderate patients, with some data showing similar rates of abnormalities as for severe patients, and some showing lower rates. In the Huang et al. cohort, at 6 months, hospitalized patients with J o u r n a l P r e -p r o o f mild-moderated disease had CT abnormalities in ~50%, similar to more severe patients; however, at 1 year, rates were significantly lower among mild-moderate patients (39%). [29, 47] Another study reported similar rates of chest CT abnormalities among 51 moderate COVID-19 recovering patients compared to more severe patients. Signs of fibrosis specifically were significantly less common among moderate patients. [51] In another study, CT abnormalities at 6 months were significantly less common among moderate (~3%) compared to severe patients (53%). [43] Recommendation: Evidence is insufficient to provide a recommendation for or against chest imaging. Chest CT should be considered at 3-6 months in patients with dyspnea or abnormal PFTs, regardless of symptoms, in order to rule out other causes and identify fibrotic changes.

Investigating patients with dyspnea, cardiac complains, and fatigue:

 Cardiac imaging Reports on severe cardiac complications (pericarditis, myocarditis, heart failure and cardiac arrhythmias) post-COVID-19 have been published, though causality is not always evident.

One observational study showed that 27.5% (14/51) of patients admitted for evaluation of cardiac symptoms (chest pain, palpitations, effort dyspnea, edema) 2 months after acute COVID-19 were diagnosed with a severe cardiovascular complications. [64] However, this reflects the most severe end of the spectrum, due to selection bias. Another study assessed patients referred to outpatient cardiology evaluation in the first 3 months following mildmoderate disease and reported echocardiographic (TTE) abnormalities in 25% (38/150), mostly reduced ejection fraction (EF), elevated pulmonary artery pressure, diastolic dysfunction, and thickened pericardium. [65] Additional studies demonstrated considerable J o u r n a l P r e -p r o o f rates of TTE findings in asymptomatic people 30-100 days post COVID-19, including reduction in left ventricular global longitudinal strain (LVGLS), diastolic dysfunction, and pulmonary hypertension. [66, 67] At a similar follow up duration, for symptomatic patients with variable severity, a systematic review reported echocardiographic findings including diastolic dysfunction in up to 55% of individuals tested; reduced left ventricular ejection fraction in up to 16%; and pulmonary hypertension in up to 10%. [40] Cardiac MRI studies have shown common abnormalities ranging 19-71%, found in recovering patients at 1-4 months. [63, [68] [69] [70] [71] These findings usually did not correlate with symptoms and were temporary, as suggested by Joy at el., demonstrating resolution of findings at 6 months following diagnosis. [72] Data from systematic reviews including variable severity of acute COVID-19 population at a follow up of 14-180 days, cardiac MRI abnormalities were reported with wide variability, and in up to 60-73% of tested patients. In four studies reporting formal diagnoses using cardiac MRI, myocarditis was reported in 0%-37%; myopericarditis 0%-11%; pericarditis 0%-3%; and myocardial infarction 0%-2%. [40, 73] Recommendation: Evidence is insufficient to provide recommendations for or against any of the above cardiac tests. Considering TTE is a non-invasive test, it may be offered for patients presenting with persistent symptoms suggestive of peri-myocardial injury (chest pain, palpitations, signs and symptoms of heart failure). It is reasonable that for patients who had cardiac abnormalities during the acute disease (myocarditis, pericarditis, heart failure) a repeat TTE would be performed at 2-3 months. Further investigation for cardiac abnormalities should be performed according to symptoms in patients presenting with cardiac symptoms. Cardiac MRI should only be performed on a case-by-case basis with a specific clinical question in mind (e.g., athletes returning to physical activity). and long COVID patients using these methods and mostly found moderate to severe impairment that correlated with acute disease severity. [42, 47, 50, 51, [74] [75] [76] [77] Specifically for the 6MWT, individuals recovering from COVID-19 exhibited inconsistent results in this test, depending on disease severity. In general, the mild to moderate limitation that was evident during the first few months following the acute illness abated with time. A small comparative study found pulmonary rehabilitation to be effective in improving the physical capacity of recoverees, as reflected by the 6MWT. [78] For 6MWT according to disease severity in individual studies see Supplemental Table 2 . Cardiopulmonary stress testing (CPET) can potentially reveal the mechanisms leading to subjective symptoms in individuals with long COVID. This has the potential to guide rehabilitation efforts. Although most studies assessed previously hospitalized individuals and found at least mild impairment months later, data gathered thus far have reached conflicting results with respect to the pathophysiological mechanism contributing to dyspnea and effort intolerance (see Table 5 for relevant studies).

Further research with appropriate control arms is warranted.

Recommendation: Evidence is insufficient to provide recommendations for or against any of the above functional test. Consider performing at the beginning of an interventional/rehabilitation program to assess progress.

Investigating patients with neurocognitive complains:

Few small studies have assessed brain imaging in long COVID patients. (See Table 5 They found specific areas of hypometabolism that were associated with symptoms of hyposmia/anosmia, memory/cognitive impairment, pain and insomnia, and that were significantly distinguished from the control group. [79] These findings were also demonstrated in smaller studies. [80] Raman et al. conducted a prospective study including 58 participants 2-3 months after acute moderate-severe COVID-19, with matched controls.

Of the study cohort, 53 performed brain MRI, with 32 showing abnormalities and higher rates of pathology in thalamus and sagittal stratum compared to controls. Periventricular white matter hyperintensities demonstrated in the study group did not correlate with cognitive impairment. [63] Recommendation: Limited evidence does not support use of brain imaging for investigating long COVID complaints, other than for ruling out other causes or for research purposes.

Anxiety, depression, and post-traumatic stress disorder were reported in 16-47% of hospitalized COVID patients within 2-3 months of discharge, with no comparison to a control J o u r n a l P r e -p r o o f group. [81, 82] In a large retrospective cohort of 236,379 patients followed for 6 months post COVID-19, the estimated incidences of mood, anxiety, or psychotic disorders were higher compared to patients following other respiratory infections. Substance use disorders and insomnia were more common as well. Incidences of anxiety and psychotic disorder were 17% an 1.2%, respectively, for the entire cohort, but were higher in hospitalized and specifically ICU patients. [83] Recommendations regarding psychological/psychiatric assessment are beyond the scope of these guidelines. Nevertheless, healthcare practitioners should be aware of the substantial incidence of psychological sequelae of COVID-19 of any severity, and, whenever relevant, refer patients for relevant assessment and therapy.

The studies included are summarized in Table 6 . Recommendation: Evidence is insufficient to provide a recommendation for or against the intervention. It is advisable to perform individualized risk stratification of risk for thrombotic event vs hemorrhagic event. Consider extended anticoagulation prophylaxis for patients with low risk of bleeding and elevated risk for VTE (active malignancy, immobility, history of VTE, recent major surgery, thrombophilia).

A meta-analysis and systematic review of RCTs was conducted to evaluate the effectiveness One small RCT included in the meta-analysis evaluated elderly patients discharged from hospital following COVID-19, and demonstrated significant improvement in pulmonary function test, 6MWT, quality of life scale and anxiety score with the intervention [90] (Table   6) .

A living systematic review evaluated rehabilitation specifically in COVID-19, both acute and post-acute phases, with one of the addressed questions being "what is the evidence for effect of intervention for limitation(s) of functioning?". [91, 92] Only three comparative studies were available for this question, addressing different patients and comparisons. (See Table 6) One of these studies is the RCT by Liu et al. described above. [93] [94] [95] Additional studies J o u r n a l P r e -p r o o f presented in this SR included non-comparative studies, all reporting significant improvement in symptoms, respiratory and general functional in response to the intervention. (Table 6) Explicit timing of starting rehabilitation could not be provided from the literature. The British Society of Rehabilitation Medicine recommends that rehabilitation start on patient's admission, and continued throughout hospitalization and then following discharge. [96] Other guidelines for rehabilitation after critical illness in general recommend initiating rehabilitation programs within the first 30 days (at the post-acute phase). [97] Rehabilitation program should include, according to individual patient, exercise rehabilitation, pulmonary, cardiac, musculoskeletal, neurological, and psychological rehabilitation. [96, 98] Recommendation: Evidence is insufficient to provide a recommendation for or against the intervention specifically for COVID-19. No data regarding persistent long COVID were identified. Until further evidence accumulates, it is reasonable that clinicians follow available consensus statements regarding multidisciplinary rehabilitation in the post-acute stage. [98] How should persistent pulmonary symptoms/signs be managed?

In one small non-comparative prospective study, 30 patients who were diagnosed as having interstitial lung disease consistent with organizing pneumonia at 6-weeks post-discharge (persistent symptoms, functional or physiological abnormalities, and parenchymal abnormality on CT) were treated with corticosteroids (maximum initial dose of 0.5mg/kg prednisolone) for three weeks. All patients demonstrated significant symptomatic improvement, significant increase in gas transfer and FVC, as well as radiologic improvement. [99] In another small study, authors retrospectively reviewed their routine management of patients with abnormal CT findings at over 4 weeks following COVID-19

and desaturation, treated with corticosteroids. At a follow up at 12-14 weeks, 24 patients demonstrated improved fatigue, breathlessness and cough, as well as improved MMRC score, J o u r n a l P r e -p r o o f saturation at rest and on 6MWT, and imaging findings. [100] However, others reported significant spontaneous recovery within 12 weeks for similar patients, raising the question whether steroids are beneficial. [101] Continuing steroids for patients with persistent hypoxemia and abnormal CT at discharge and/or at follow up has been suggested based on clinical experience, though not tested in comparative clinical studies. [102, 103] Few cases of treatment of long COVID lung fibrosis with antifibrotic agents have been reported. [104] This therapeutic option is currently being tested in clinical trials. Trials are ongoing to evaluate the use of the antifibrotic nintedanib and pirfenidone, as well as other drugs [105] [106] [107] Recommendation: Evidence is insufficient to provide a recommendation for or against any intervention.

There are no clinical studies evaluating the management of persistent cough following acute COVID-19. In a review discussing possible pathophysiology and management of cough in patients with COVID-19, it has been suggested to further investigate the role of gabapentin and pregabalin, antimuscarinic drugs, and other novel drugs that interfere with the neuroinflammatory pathways. [22] Recommendation: Evidence is insufficient to provide a recommendation for or against any intervention.

A Cochrane systematic review aimed to assess interventions to treat COVID-19 persisting olfactory dysfunction in general has been discussed. In this consensus document, it is stated that benefit of smoking cessation in long COVID anosmia/ageusia is not clear, but overall benefit justifies the recommendation. Other therapies described that need further study include oral and intranasal corticosteroids, theophylline, sodium citrate, N-methyl D-aspartate antagonist (caroverine), traditional Chinese acupuncture, a-lipoic acid, vitamin A, minocycline, and zinc sulfate. [109] One low quality RCT including 100 recovering COVID-19 patients evaluated topical corticosteroid nasal spray (mometasone furoate) for 3 weeks, combined with olfactory training, versus olfactory training alone. In this study, no difference between groups was demonstrated in rates or patients with olfactory recovery or duration of anosmia/hyposmia. For the latter, various interventions have been suggested. [5, 112] Systematic reviews of such interventions included various medications, complementary and alternative medicine, cognitive behavioral therapy, and exercise. The included studies were heterogeneous and data were limited, although the drug rintatolimod, counselling therapies, and graded exercise therapy suggested benefit. [113, 114] No evidence is available to support interventions for managing fatigue in long COVID patients. Graded exercise and cognitive behavioral therapy are controversial for the management of ME/CFS and should be further investigated for long COVID patients prior to any recommendation. [114, 115] Recommendation: Evidence is insufficient to provide a recommendation for or against any intervention.

There are no clinical studies evaluating any pharmacological treatment for neurological sequelae of long COVID. The flavonoid luteolin has been suggested as a potential treatment, by inhibiting a pro-inflammatory cascade of mast cells and microglia activation in the J o u r n a l P r e -p r o o f hypothalamus. However, no studies have evaluated this intervention. [116] The cannabis derivatives cannabidiol and cannabivarin have been suggested to have the potential to bind to central nervous system proteins related to long COVID symptoms and downregulate them.

These compounds have not been tested in clinical studies. [117] Methylene blue has been suggested as a possible therapy for neurocognitive impairment in long COVID due to its mitochondrial protective effects. [118] The therapeutic potential is theoretical, however, without clinical evidence.

Recommendation: Evidence is insufficient to provide a recommendation for or against any intervention.

Clomipramine, a tricyclic antidepressant with anti-inflammatory action and penetrance to central nervous system, has been suggested as a potential drug to prevent post-infectious mental complications. Further studies are needed. [119] Recommendation: Evidence is insufficient to provide a recommendation for or against any intervention.

As reflected in these guidelines, studies on long COVID are limited by the lack of a consistent definition of long COVID in terms of symptoms and timeframes; absence of typical laboratory findings/diagnostic tests; and absence of a comparison group in most studies. Selection bias might be pronounced due to the considerable portion of online recruitment studies. [120] In addition, design is usually retrospective, including symptomatic J o u r n a l P r e -p r o o f patients (rather than all recovering patients), thus limiting the ability to measure the scope of the problem and evaluate risk factors.

Additional studies are needed, including studies following consecutive patients recovering from COVID-19, with various severities of the acute disease. Such studies should be designed to evaluate the incidence of long COVID, and to identify risk factors for its development. The first priority would be to evaluate healthy, community treated persons, to evaluate the scope of the problem in this population and the need for follow up. Considering the toll of stressful pandemic, quarantine and unemployment, Amin-Chowdhury et al.

suggested prospective longitudinal cohort studies using a non-infected control group. [120] Clustering of symptoms may assist in evaluating the scope of illness, compared to noninfected people, and evaluate risk factors. Amin-Chowdhury et al. described the following clusters in a large prospective cohort: sensory cluster (ageusia, anosmia, loss of appetite and blurred vision), neurological cluster (forgetfulness, short-term memory loss and confusion/brain fog), and cardiorespiratory cluster (chest tightness/pain, unusual fatigue, breathlessness after minimal exertion/at rest, palpitations). [121] Patients following ICU hospitalization should be addressed separately in studies, including studies assessing rehabilitation starting in hospital, and different interventions to prevent and treat lung injury.

Less severe patients should be investigated for interventions to resolve their leading symptom / cluster of symptoms (as descried above). Outcomes addressed should include return to work and return to previous activity level, including sports. Further research is also needed to elucidate the pathophysiology of long COVID various symptoms. Additional studies should assess long COVID prevalence and symptoms following different SARS-CoV-2 variants, and following vaccination.

Long term follow-up studies on symptomatic patients are needed to evaluate assessment and management interventions, using pre-defined patient-related outcomes including quality of life, time to return to work and baseline physical activity, and cognitive and functional assessment. These studies should be RCTs. 

All authors declare none.

None among ESCMID members; we thank Virginie Prendki, Miriam Weinberger, and Petar Velikov, for critical review of the draft guideline.

These are rapid guidelines aimed to capture current evidence on the topic. However, due to the rapid evolvement of the literature, we plan to conduct these as living guidelines to be modified with upcoming new evidence. The panel will meet monthly regarding the need for updates. The panel members will perform an updated search every three months and will update the guidelines once substantial evidence for changing any recommendation will be observed.

J o u r n a l P r e -p r o o f $ Reference: [25] § Reference: [28, 29, [123] [124] [125] J o u r n a l P r e -p r o o f Table 4 . Prevalence of long COVID symptoms in studies investigating patients regardless of disease severity and in studies in hospitalized patients. [23, 25, 28, 47, 55, 74, 123, 124, [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] . Compared with healthy controls, the peak oxygen consumption was decreased [81% (SD 23%) of expected] (p<0.0001). Of all recoverees, 28/51 (55%) had peak oxygen consumption <80% of predicted.

Patients recovering from COVID-19 had symptoms associated with reduction in peak oxygen consumption. 8/71 (11%) had peak oxygen consumption <85% of predicted.

Peak oxygen consumption is reduced to an average of 83% ± 15% of predicted. Exercise capacity is not associated with severity of COVID-19.

Of the entire sample 6/31 (19%) had pulmonary-vascular limitations, 5/31 (16%) had pulmonary-mechanical limitations, 4/31 (13%) had deconditioning, and 1/31 (3%) had cardiac capacity limitation.

Mean peak oxygen consumption was 73% of predicted. The main reason for dyspnea is suspected to be muscular. Higher rates vs control group of higher T2* signal on susceptibility-weighted imaging in the left and right thalamus; increased mean diffusivity in the left posterior thalamic radiation and left and right averaged sagittal stratum Compared to controls, volumetric and micro-structural abnormalities were detected mainly in the central olfactory cortices, partial white matter in the right hemisphere

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients

Updated estimates of the prevalence of long COVID symptoms 21-Jan_2021

Long COVID has exposed medicine's blind-spot. The Lancet Infectious Diseases 2021

NICE guideline on long covid

Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management

Haute autorite de sante. Fiches réponses rapides dans le cadre du COVID-19 de la HAS -Symptômes prolongés suite à une Covid-19 de l'adulte -Diagnostic et prise en charge

Living guidance for clinical management of COVID-19

COVID-END. COVID-19 Evidence Network to support Decision-making

Cochrane library spceial collections. Coronavirus (COVID-19 n

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions

The GRADE system for rating clinical guidelines

WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus

COVID-19 and Your Health

NIH launches new initiative to study "Long COVID

More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis

Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses

Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis

Follow-Ups on Persistent Symptoms and Pulmonary Function Among Post-Acute COVID-19 Patients: A Systematic Review and Meta-Analysis

Characterising long COVID: a living systematic review

Long-Term Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis

A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome

Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19)

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

Post-acute COVID-19 syndrome

Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol

Female gender is associated with long COVID syndrome: a prospective cohort study

Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh

Evolving phenotypes of non-hospitalized patients that indicate long COVID

Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients-A Prospective Multicenter Cross-Sectional Study

Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Monaldi Hospital Cardiovascular Infection Study Group. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review

COVID-19-Associated Subacute Thyroiditis: Evidence-Based Data From a Systematic Review

Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission

A Follow-Up Study of Lung Function and Chest Computed Tomography at 6 Months after Discharge in Patients with Coronavirus Disease 2019

Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up

Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Clinical status and lung function 10 weeks after severe SARS-CoV-2 infection

Evolution of lung function and chest CT 6 months after COVID-19 pneumonia: Real-life data from a Belgian University Hospital

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Comprehensive health assessment three months after recovery from acute COVID-19

Symptomatic, biochemical and radiographic recovery in patients with COVID-19

Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia

Radiological management and follow-up of post-COVID-19 patients

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae

Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients

Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia

Mediumterm effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

COVID-19 and cardiovascular complications -preliminary results of the LATE-COVID study

Associations between the Severity of the Post-Acute COVID-19 Syndrome and Echocardiographic Abnormalities in Previously Healthy Outpatients Following Infection with SARS-CoV-2

Elevated high-sensitivity troponin is associated with subclinical cardiac dysfunction in patients recovered from coronavirus disease 2019

Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial

Cardiac involvement in consecutive elite athletes recovered from Covid-19: A magnetic resonance study

Cardiac T1 and T2 Mapping Showed Myocardial Involvement in Recovered COVID-19 Patients Initially Considered Devoid of Cardiac Damage

Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study

Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers

Cardiac Magnetic Resonance Imaging Findings

Adult Survivors: A Comprehensive Systematic Review. Journal of Magnetic Resonance Imaging : JMRI 2021

Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge

Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life

lung function and CT findings 3 months after hospital admission for COVID-19

A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations

Six-month outcomes and effect of pulmonary rehabilitation among patients hospitalized with COVID-19: a retrospective cohort study

18F-FDG brain PET hypometabolism in patients with long COVID

18F-FDG-PET Imaging for Post-COVID-19 Brain and Skeletal Muscle Alterations

Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients

A living systematic review of the psychological problems in people suffering from COVID-19

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Antithrombotic Therapy in Patients With COVID-19 11-Feb_2021

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

COVID-19 and VTE/Anticoagulation: Frequently Asked Questions n.d

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

EFFECTIVENESS OF PULMONARY REHABILITATION IN INTERSTITIAL LUNG DISEASE INCLUDING CORONAVIRUS DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study

Rehabilitation and COVID-19: the Cochrane Rehabilitation 2020 rapid living systematic review

Rehabilitation and COVID-19: a rapid living systematic review by Cochrane Rehabilitation Field updated as of December 31st, 2020 and synthesis of the scientific literature of 2020

Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study

Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU

Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study

British Society of Rehabilitation Medicine

Overview | Rehabilitation after critical illness in adults | Guidance | NICE n

The Stanford Hall consensus statement for post-COVID-19 rehabilitation

Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment

Systemic corticosteroids for management of "long-COVID": an evaluation after 3 months of treatment. Monaldi Arch Chest Dis

A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?

Care of the postcoronavirus disease 2019 patient

Post-COVID lung fibrosis: The tsunami that will follow the earthquake

Usefulness of Pirfenidone in Covid Lung: A Case Series

A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia. clinicaltrials.gov

Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis. clinicaltrials.gov

Lung Fibrosis after COVID-19: Treatment Prospects

Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction

Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial

Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluation

Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology

Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?

NICE draft guidance addresses the continuing debate about the best approach to the diagnosis and management of ME/CFS | News and features | News

Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue

Insilico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration

Methylene blue: Subduing the post COVID-19 blues!

The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection

Causation or confounding: why controls are critical for characterizing long COVID

Characterising long COVID more than 6 months after acute infection in adults

Incidence of Long-term Postacute Sequelae of SARS-CoV-2 Infection Related to Pain and Other Symptoms: A Living Systematic Review and Meta-analysis

Prevalence and Risk Factors for Post-Traumatic Stress in Hospitalized and Non-Hospitalized COVID-19 Patients

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Assessment of Sequelae of COVID-19 Nearly

Year After Diagnosis

Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19

Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort

Persistent post-covid symptoms in healthcare workers

Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables

Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

Long COVID in the Faroe Islands -a longitudinal study among non-hospitalized patients

Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study

Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19

Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study

Ninety days post-hospitalization evaluation of residual COVID-19 symptoms through a phone call check list

What is Long-COVID and How Should We Manage It?

Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients

Posttraumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge

Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Characteristics of Long Covid: findings from a social media survey

Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis

Overview of Symptoms of Ongoing Symptomatic and Post-COVID-19 Patients Who Were Reffered to Pulmonary Rehabilitation -First Single-Centre Experience in Croatia

Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea

Evidence for impaired chronotropic responses to and recovery from 6-minute walk test in women with post-acute COVID-19 syndrome

One year follow-up of physical performance and quality of life in patients surviving COVID-19: a prospective cohort study

Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic

Coronavirus Disease 2019: COSeSco -A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae

Long-term consequences in critically ill COVID-19 patients: A prospective cohort study

Long-term impact of COVID-19 associated acute respiratory distress syndrome

Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan

Use of sit-to-stand test to assess the physical capacity and exertional desaturation in patients post COVID-19

Exercise Testing in Patients with Post-COVID-19 Syndrome

Cardiorespiratory Abnormalities in Patients Recovering from Coronavirus Disease

Severity does not impact on exercise capacity in COVID-19 survivors

Long COVID: Distinction between Organ Damage and Deconditioning

Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19

Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning

Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations

Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation

Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea

Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease

Cerebral Micro-Structural Changes in COVID-19 Patients -An MRI-based 3-month Follow-up Study

Effectiveness of structured exercise protocol on functional performance in subjects with COVID-19

Feasibility and Efficacy of Cardiopulmonary Rehabilitation After COVID-19

Rehabilitation in adult post-COVID-19 patients in post-acute care with Therapeutic Exercise

Do Patients With COVID-19 Benefit from Rehabilitation? Functional Outcomes of the First

Rehabilitation Unit

Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study

Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study

Effectiveness of pulmonary rehabilitation in COVID-19 respiratory failure patients post-ICU

Adverse Outcomes of Home Health Recipients

Ottawa score; PFT -pulmonary function tests; DLCO -diffusing capacity for carbon monoxide; TLC -total lung capacity

FEV1 -forced expiratory volume; FVC -forced vital capacity; CXR -chest X-ray

ARDS -acute respiratory distress

MV -mechanical ventilation; PAP -pulmonary artery pressure; LVGLS -left ventricular global longitudinal strain; 6MWT -6-minute walk test

SPPB -short physical performance battery; SPO2 -peripheral capillary oxygen saturation

The medical writing assistance by Patrick Moore and methodology direction and overview by Luigia Scudeller are acknowledged. We also acknowledge the technical assistance by Chiara Speziale. We thank other ESCMID COVID-19 guidelines panel members for the discussions and advice. As per ESCMID procedures, the manuscript did undergo a public consultation J o u r n a l P r e -p r o o f